The study of advanced NSCLC that evaluated PD-L1 expression in 187 cases found that PD-L1 TPS ≥ 1% was in 59.9% cases, while PD-L1 CPS ≥ 1% was in 72.2% cases. Here, CD274 is linked to non-small cell lung carcinoma.